Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia Patients

NCT05413915 is registered in ClinicalTrials.gov with Sarit Assouline as lead sponsor.

NCT NCT05413915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia Patients
Lead sponsor
Sarit Assouline
Phase
Phase 3
Overall status
Terminated
Start date
November 1, 2023
Completion date
July 2, 2025
Enrollment
8 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic myeloid leukemia in remission, chronic myeloid leukemia, bcr/abl-positive